Skip to content

    JB Chemicals & Pharmaceuticals Limited

    JBCHEPHARMGood
    Healthcare·7 Nov 2024
    Management Summary

    J B Chemicals delivered a strong Q2 FY25, crossing the ₹1,000 crore revenue milestone driven by robust 22% growth in the domestic market. While the CDMO segment faced temporary supply chain headwinds that deferred $2 million in sales to Q3, management remains confident in its long-term $100 million revenue target for the segment. The company continues to maintain industry-leading margins of ~28% while aggressively scaling its acquired chronic and ophthalmology portfolios.

    Highlights

    8

    • Revenue reached ₹1,001 crore for the quarter, representing a 13% YoY increase.

    • Domestic business grew 22% YoY to ₹588 crore, significantly outperforming the Indian Pharmaceutical Market (IPM).

    • Operating EBITDA (excluding ESOP) stood at ₹285 crore with a margin of 28.4%.

    • Net profit increased by 16% YoY to ₹175 crore.

    • International business revenue grew 3% to ₹413 crore, impacted by a $2 million CDMO sale deferment.

    • Gross margins remained steady at 66.2%, aided by favorable product mix and price growth.

    • The company reduced gross debt significantly to ₹82 crore from ₹358 crore in March 2024.

    • Ophthalmology portfolio, integrated in Jan '24, grew 19% sequentially over Q1 FY25.

    What Changed1

    vs Q3 FY25

    Guidance items6 → 5 (-1)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹1,001 Cr+13%YoY
    2. 02Operating EBITDA Margin28.4%
    3. 03Net Profit₹175 Cr+16%YoY
    4. 04Gross Margin66.2%
    5. 05Gross Debt₹82 Cr-77%YoY

    Segment breakdown

    • Domestic Business₹588 Cr58.7%
    • International Business₹413 Cr41.3%
    Donut· Share of Revenue

    Guidance & targets

    5
    CategoryTargetPriority
    Margin
    Operating EBITDA Margin
    26%-28%
    		High
    Revenue
    CDMO Business Revenue
    $100 million
    		Medium
    Capex
    Total Capex
    ₹100+ crore
    		High
    Volume
    Azmarda Monthly Run Rate
    140,000-145,000 units
    		High
    Other
    Net Operating Cash to EBITDA conversion
    +80%
    		High

    Risks & concerns

    4
    RiskSeverity

    CDMO Raw Material Availability

    Specific excipients from regulated markets were delayed, deferring $2M in sales to Q3 FY25. — Management acknowledged

    medium

    Currency Volatility (Ruble)

    MTM FOREX impact of ₹4 crore recorded in Q2 due to Ruble depreciation. — Management acknowledged

    low

    Inventory Normalization

    Management expects a marginal impact in Q4 due to inventory normalization in the India business. — Management acknowledged

    low

    Areas of Evasion(1)

    • Refusal to provide a market-wise split for the 20 new international filings due to 'business specific strategy'.

    Q&A highlights

    3

    “it is now close to $50 million, we want to take it $100 million in 3-5 years... you should see business ramping up because couple of million dollar got deferred in quarter 3 because of the material availability.”

    Confirms that the CDMO slowdown in H1 was due to temporary supply issues rather than structural demand loss.

    asked by Amey, JM Financial

    2 min read5 chapters

    Detailed Narrative

    01

    Domestic Business Outpaces Market Growth

    The domestic business delivered a stellar 22% YoY growth, reaching ₹588 crore. Even excluding the new Ophthalmology portfolio, organic growth stood at 12.6%, significantly higher than the IPM growth of 7.6%. All top five brands are now among the top 150 in the country, with the company jumping from rank 15 to 8 in the Cardiology market since 2021.

    02

    CDMO Segment: Temporary Headwinds vs. Long-term Targets

    The CDMO business was muted in H1 FY25 due to material availability challenges, specifically unique excipients from regulated markets. This resulted in $2 million of sales being deferred from Q2 to Q3. Despite this, management reiterated its target to double the business from ~$50 million to $100 million in the next 3-5 years, supported by a robust order book for H2 FY25.

    03

    Ophthalmology Integration and Prescriber Expansion

    The Ophthalmology portfolio, integrated in January 2024, is scaling rapidly with 19% sequential growth in Q2. Prescriber coverage has nearly doubled from 7,000 to 13,500 ophthalmologists, with a target to reach 16,000-17,000 in the next 12 months. The company plans to launch a new product in this segment every three months to fill unmet needs in glaucoma, pain, and anti-allergics.

    04

    Financial Discipline and Margin Guidance

    Management reiterated its operating EBITDA margin guidance of 26%-28% for FY25. Gross margins improved by over 150 bps YoY (excluding Ophthalmology) due to cost optimization and favorable product mix. The company has also significantly deleveraged, reducing gross debt from ₹358 crore in March to just ₹82 crore in September 2024.

    05

    Strategic Focus on Chronic Portfolios

    The thrust on chronic and high-growth portfolios remains central to the strategy. Azmarda is projected to grow at 15%-20% CAGR for the next 5 years, while the Razel franchisee grew 28% YoY. The company is also focusing on lifecycle management (LCM) for mature brands like Metrogyl and Rantac through new extensions like Metrogyl ER and Rantac OD to maintain growth.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.